Gilead Sciences Inc
NASDAQ: GILD
$92.38
+$1.38 (+1.5%)
Closing Price on January 15, 2025
GILD Articles
These are the top ten analyst research initiations, upgrades, and downgrades we have seen from top Wall Street firms early this Wednesday morning: Biogen-Idec (BIIB) Started as Underperform at...
Published:
The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis...
Published:
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market....
Published:
Last Updated:
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
Published:
Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early afternoon Thursday after Japan okayed one of the company’s human growth hormones, the first approval...
Published:
Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of the lessons of scares in the past of SARS, bird flu, Mad Cow, and even hoof & mouth as...
Published:
Last Updated:
Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash.
Published:
Last Updated:
Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know is if these results — or more importantly its guidance — show that this...
Published:
Last Updated:
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to...
Published:
Last Updated:
It is getting pretty thin in major analyst coverage as firms are encouraged to go easy on major year-end calls barring anything unexpected. These are the top analyst upgrades, downgrades, and new...
Published:
Last Updated:
These are the top pre-market upgrades and positive analyst calls we have seen from Wall Street this Monday morning: Altria (NYSE: MO) Raised to Overweight at JPMorgan. Best Buy (NYSE: BBY) Raised to...
Published:
Last Updated:
It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be one...
Published:
Gilead Sciences Inc. (NASDAQ: GILD) has just issued its third quarter earnings at $0.52 net EPS and $0.55 non-GAAP EPS and $1.37 billion in revenue. First Call had estimates at $0.49 non-GAAP EPS...
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) is trading down this morning. Goldman Sachs maintained its buy rating on the stock, but took down its price target to $58 from $59. This report is after a...
Published:
Last Updated:
There are surprisingly few analyst calls today, but these are some of the top positive calls and upgrades with more than two hours to the market open: Diebold (DBD) Raised to Buy at Wedbush Morgan....
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.